Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Endocrinology | Gastroenterology | Oncology | Family Medicine
Search Medical Condition
Pancreatic Cancer Clinical Trials
A listing of Pancreatic Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (608) clinical trials
A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
You are being asked to take part in this study because you have pancreatic cancer that was removed by surgery. You are eligible for this study because there was no visible cancer left behind and not more than 10 weeks have passed since your operation. Patients were first randomized (assigned ...
A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
You are being asked to take part in this study because you have pancreatic cancer that can be removed by surgery. People who are not in a study are usually treated with surgery first and then with chemotherapy drugs approved by the Food and Drug Administration (FDA). Sometimes radiation is ...
Study title: A randomized, double blind, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
This clinical study evaluates the efficacy and safety of regorafenib in patients with advanced liver cancer who have progressed on sorafenib treatment. Approximately 560 patients who meet the entry criteria will be randomly assigned in a 2:1 ratio to regorafenib or placebo (1/3 chance to receive placebo). Primary endpoint of ...
Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC
This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or lymph nodes or has spread to other places in the body. Sorafenib tosylate may stop ...
A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)
This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients who are candidates for potentially ...
Learn
A research study is evaluating an investigational treatment for renal cell carcinoma (RCC). This research study may be an option if you: Are at least 18 years of age Have a confirmed diagnosis of RCC Have had a recent nephrectomy procedure Other criteria apply. Please make sure to discuss with ...
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
The purpose of this study is evaluate the efficacy of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
Study of Copanlisib in Hepatic or Renal Impairment
To evaluate the pharmacokinetics and safety of copanlisib in subjects with impaired hepatic or renal function in comparison to healthy subjects
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
The purpose of this study is evaluate the efficacy of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in subjects with mesothelin-expressing advanced solid cancers
